Results for tag: "Reteplase"

Reteplase is a recombinant form of tissue plasminogen activator (tPA) used in the treatment of cardiovascular diseases. It is a thrombolytic agent, meaning it helps to dissolve blood clots that can cause heart attack and stroke. It is administered intravenously and works by activating plasminogen, an enzyme that breaks down fibrin, a protein that forms the basis of a clot. Reteplase is used to treat acute myocardial infarction (AMI) and ischemia, a condition in which the heart does not receive enough oxygen-rich blood. It is also used to treat pulmonary embolism, a condition in which a clot blocks the flow of blood to the lungs. Reteplase is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 1998. It is used in combination with other drugs, such as aspirin and heparin, to treat cardiovascular diseases. It is generally considered to be a safe and effective treatment for AMI and ischemia. The Reteplase market is highly competitive, with several companies offering the drug. These include Sanofi, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more